DOCSLIB.ORG

Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America How to Cite the Adult and Adolescent Opportunistic Infection Guidelines: PanelHow to onCite Opportunistic the Adult and Adolescent Infections Opportunistic in Adults and Infection Adolescents Guidelines: with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the preventionthe Centers and for treatment Disease of opportunisticControl and infections Prevention, in adults the andNational adolescents Institutes with HIV of : Health, and the HIV Medicine recommendationsAssociation of the from Infectious the Centers Diseases for Disease Society Control ofand America. Prevention, Available the National at https://clinicalinfo.hiv.gov/sites/Institutes ofdefault/files/guidelines/documents/Adult_OI.pdf Health, and the HIV Medicine Association of the Infectious. Accessed Diseases (insertSociety ofdate)[include America. page numbers, table Availablenumber, at etc. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf if applicable] . Accessed (insert date) [include page numbers, table number, etc. if applicable] It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanism to It is emphasized that concepts relevant to HIV management evolve rapidly. The Panel has a mechanismupdate recommendations to update recommendations on a regular on a regularbasis, basis,and theand mostthe most recent recent information information is is available onAccess the Clinical AIDSinfo availableInfo website on the ( Ahttps://clinicalinfo.hiv.govIDSinfo website (http://aidsinfo.nih.gov). ). mobile site What’s New in the Guidelines Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV document is published in an electronic format that can be easily updated as relevant changes in prevention and treatment recommendations occur. The editors and subject matter experts are committed to timely changes in this document because so many health care providers, patients, and policy experts rely on this source for vital clinical information. All changes are developed by the subject matter groups listed in the document (changes in group composition are also promptly posted). These changes are reviewed by the editors and by relevant outside reviewers before the document is altered. Major revisions within the last 6 months are as follows: June 28, 2021 Cytomegalovirus: Key updates to the guidelines include the following: • Updated to improve readability and to update references. • Highlighted the toxicities of alternative antiviral medications used to treat CMV. Cryptococcosis: Key updates to the guidelines include the following: • Recommended an increase in the dose of fluconazole from 400 mg to 800 mg daily for consolidation therapy. For clinically stable patients who have been started on ART and whose CSF culture results return with no growth, the dose can be decreased to 400 mg daily. • Included results of a trial in a resource-limited setting that used only one week of amphotericin B induction therapy but did NOT recommend this approach for high-resource settings. • Clarified that the treatment of non-CNS extrapulmonary cryptococcosis and diffuse pulmonary disease should be the same as that for meningitis and that treatment of mild-moderate focal pulmonary infection should be with fluconazole, 400-800 mg daily. • Clarified treatment for patients who have been found to have asymptomatic antigenemia. For patients whose serum titer is <1:320 using a lateral flow assay, treatment can be with fluconazole 400-800 mg daily. For patients whose serum titer is >1:640, the likelihood that meningitis is present or will develop is high, and treatment should be the same as that for cryptococcal meningitis. • Revised the Pregnancy text for consistency with other sections of the guidelines. • Revised the table of recommendations to clarify recommended treatment of the various forms of cryptococcosis in persons with HIV. June 11, 2021 Coccidioidomycosis: Key updates to the guidelines include the following: • Revised section on serology for the diagnosis of coccidioidomycosis • Added PCR as a commercially available diagnostic test • Revised the section on patients who are asymptomatic with a positive serological test Bartonellosis: Key updates to the guidelines include the following: • Updated section on diagnostics, including role of PCR-based testing • Updated section on treatment for endocarditis Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV i Immunizations for Preventable Diseases in Adults and Adolescents Living with HIV: Key updates to the guidelines include the following: • Revised figure summarizing immunizations in PLWH • Added table comparing ACIP recommendations with Panel recommendations • Added narrative sections with evidence summaries • Updated recommendation for zoster vaccine May 26, 2021 Immunizations Table, Text, and Figure: The Panel updated the text, references, figure, and table and made the following key changes: • Revised layout of figure • Addition of table outlining ACIP recommendations and Panel recommendations, and highlighted potential differences • Addition of narrative sections with evidence summaries Key updates to the guidelines include the following to the Coccidiomycosis section: • The Panel has simplified the section on serology for the diagnosis of coccidioidomycosis and added PCR as a non-standardized, but commercially available test. • In the Preventing Disease section, the Panel clarified the approach to patients who are asymptomatic but have a positive serological test for Coccidioides based on CD4 counts <250 cells/μL or >250 cells/μL. • Treating Disease section is more clearly written regarding recommendations for treating mild-moderate pulmonary disease and severe pulmonary/extrathoracic (disseminated) disease. • In Pregnancy, the text has been revised to that used in other sections of the guidelines. • The table of recommendations has been revised to clarify recommended treatment of mild-moderate pulmonary disease, severe pulmonary/extrapulmonary (disseminated) disease, and meningitis. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV ii Table of Contents What’s New in the Guidelines ..........................................................................................................................i Introduction ..................................................................................................................................................A-1 Bacterial Enteric Infections ........................................................................................................................ B-1 Bartonellosis ................................................................................................................................................. C-1 Candidiasis (Mucocutaneous) .....................................................................................................................D-1 Chagas Disease ............................................................................................................................................. E-1 Coccidioidomycosis .......................................................................................................................................F-1 Community-Acquired Pneumonia .............................................................................................................G-1 Cryptococcosis ..............................................................................................................................................H-1 Cryptosporidiosis .......................................................................................................................................... I-1 Cystoisosporiasis ........................................................................................................................................... J-1 Cytomegalovirus Disease .............................................................................................................................K-1 Hepatitis B Virus Infection ......................................................................................................................... L-1 Hepatitis C Virus Infection ........................................................................................................................ M-1 Herpes Simplex Virus Disease .....................................................................................................................N-1 Histoplasmosis ..............................................................................................................................................O-1 Human Herpesvirus-8 Disease .....................................................................................................................P-1 Human Papillomavirus Disease ..................................................................................................................Q-1
Load more

Recommended publications
  • Miltefosine Combined with Intralesional Pentamidine for Leishmania Braziliensis Cutaneous Leishmaniasis in Bolivia
    Am. J. Trop. Med. Hyg., 99(5), 2018, pp. 1153–1155 doi:10.4269/ajtmh.18-0183 Copyright © 2018 by The American Society of Tropical Medicine and Hygiene Miltefosine Combined with Intralesional Pentamidine for Leishmania braziliensis Cutaneous Leishmaniasis in Bolivia Jaime Soto,1* Paula Soto,1 Andrea Ajata,2 Daniela Rivero,3 Carmelo Luque,2 Carlos Tintaya,2 and Jonathan Berman4 1FUNDERMA (Fundacion ´ Nacional de Dermatolog´ıa), Santa Cruz, Bolivia; 2Servicio Departamental de Salud, Departamento de La Paz, La Paz, Bolivia; 3Hospital Dermatologico ´ de Jorochito, Santa Cruz, Bolivia; 4AB Foundation, North Bethesda, Maryland Abstract. Bolivian cutaneous leishmaniasis due to Leishmania braziliensis was treated with the combination of mil- tefosine (150 mg/day for 28 days) plus intralesional pentamidine (120 μg/mm2 lesion area on days 1, 3, and 5). Ninety-two per cent of 50 patients cured. Comparison to historic controls at our site suggests that the efficacy of the two drugs was additive. Adverse effects and cost were also additive. This combination may be attractive when a prime consideration is efficacy (e.g., in rescue therapy), avoidance of parenteral therapy, or the desire to treat locally and also provide systemic protection against parasite dissemination. INTRODUCTION METHODS AND PATIENTS Cutaneous leishmaniasis (CL) in the New World gener- Study design and treatments. This was an open-label ally presents as a papule that enlarges and ulcerates over evaluation of one intervention: standard treatment with oral 1–3 months and then self-cures, but the predominant spe- miltefosine in combination with intralesional treatment with cies at our site in Bolivia, Leishmania (Viannia) braziliensis pentamidine.
    [Show full text]
  • 204684Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 204684Orig1s000 OFFICE DIRECTOR MEMO Deputy Office Director Decisional Memo Page 2 of 17 NDA 204,684 Miltefosine Capsules 1. Introduction Leishmania organisms are intracellular protozoan parasites that are transmitted to a mammalian host by the bite of the female phlebotomine sandfly. The main clinical syndromes are visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucosal leishmaniasis (ML). VL is the result of systemic infection and is progressive over months or years. Clinical manifestations include fever, hepatomegaly, splenomegaly, and bone marrow involvement with pancytopenia. VL is fatal if untreated. Liposomal amphotericin B (AmBisome®) was FDA approved in 1997 for the treatment of VL. CL usually presents as one or more skin ulcers at the site of the sandfly bite. In most cases, the ulcer spontaneously resolves within several months, leaving a scar. The goals of therapy are to accelerate healing, decrease morbidity and decrease the risk of relapse, local dissemination, or mucosal dissemination. There are no FDA approved drugs for the treatment of CL. Rarely, CL disseminates from the skin to the naso-oropharyngeal mucosa, resulting in ML. ML can also develop some time after CL spontaneous ulcer healing. The risk of ML is thought to be highest with CL caused by the subgenus Viannia. ML is characterized in the medical literature as progressive with destruction of nasal and pharyngeal structures, and death may occur due to complicating aspiration pneumonia. There are no FDA approved drugs for the treatment of ML. Paladin Therapeutics submitted NDA 204, 684 seeking approval of miltefosine for the treatment of VL caused by L.
    [Show full text]
  • Studies on the Detection Methods of Campylobacter and Faecal Indicator Bacteria in Drinking Water
    Tarja Pitkänen Tarja Pitkänen Tarja Studies on the Detection Tarja Pitkänen Methods of Campylobacter RESEARCH Studies on the Detection Methods of RESEARCH Campylobacter and Faecal Indicator Bacteria and Faecal Indicator in Drinking Water Bacteria in Drinking Water Indicator Bacteria in Drinking Water Drinking in Bacteria Indicator Methods Detection the on Studies Faecal contamination of drinking water and subsequent waterborne gastrointestinal infection outbreaks are a major public health concern. In this study, faecal indicator bacteria were detected in 10% of the groundwater samples analysed. The main on-site hazards to water safety at small community water supplies included inadequate well construction and maintenance, an insufficient depth of the protective soil layer and bank filtration. As a preventive measure, the upgrading of the water treatment processes and utilization of disinfection at small Finnish groundwater supplies are recommended. More efficient and specific and less time-consuming methods for enumeration and typing of E. coli and coliform bacteria from non-disinfected water as well as for cultivation and molecular detection and typing of Campylobacter were found in the study. These improvements in methodology for the analysis of the faecal bacteria from water might promote public health protection as they Campylobacter could be anticipated to result in very important time savings and improve the tracking of faecal contamination source in waterborne outbreak investigations. and Faecal Faecal and .!7BC5<2"HIGEML! National Institute for Health and Welfare P.O. Box 30 (Mannerheimintie 166) FI-00271 Helsinki, Finland Telephone: +358 20 610 6000 39 ISBN 978-952-245-319-8 39 2010 39 www.thl.fi Tarja Pitkänen Studies on the Detection Methods of Campylobacter and Faecal Indicator Bacteria in Drinking Water ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Science and Forestry of the University of Eastern Finland for public examination in auditorium, MediTeknia Building, on October 1st, 2010 at 12 o’clock noon.
    [Show full text]
  • Campylobacteriosis: a Global Threat
    ISSN: 2574-1241 Volume 5- Issue 4: 2018 DOI: 10.26717/BJSTR.2018.11.002165 Muhammad Hanif Mughal. Biomed J Sci & Tech Res Review Article Open Access Campylobacteriosis: A Global Threat Muhammad Hanif Mughal* Homeopathic Clinic, Rawalpindi, Islamabad, Pakistan Received: : November 30, 2018; Published: : December 10, 2018 *Corresponding author: Muhammad Hanif Mughal, Homeopathic Clinic, Rawalpindi-Islamabad, Pakistan Abstract Campylobacter species account for most cases of human gastrointestinal infections worldwide. In humans, Campylobacter bacteria cause illness called campylobacteriosis. It is a common problem in the developing and industrialized world in human population. Campylobacter species extensive research in many developed countries yielded over 7500 peer reviewed articles. In humans, most frequently isolated species had been Campylobacter jejuni, followed by Campylobactercoli Campylobacterlari, and lastly Campylobacter fetus. C. jejuni colonizes important food animals besides chicken, which also includes cattle. The spread of the disease is allied to a wide range of livestock which include sheep, pigs, birds and turkeys. The organism (5-18.6 has% of been all Campylobacter responsible for cases) diarrhoea, in an estimated 400 - 500 million people globally each year. The most important Campylobacter species associated with human infections are C. jejuni, C. coli, C. lari and C. upsaliensis. Campylobacter colonize the lower intestinal tract, including the jejunum, ileum, and colon. The main sources of these microorganisms have been traced in unpasteurized milk, contaminated drinking water, raw or uncooked meat; especially poultry meat and contact with animals. Keywords: Campylobacteriosis; Gasteritis; Campylobacter jejuni; Developing countries; Emerging infections; Climate change Introduction of which C. jejuni and 12 species of C. coli have been associated with Campylobacter cause an illness known as campylobacteriosis is a common infectious problem of the developing and industrialized world.
    [Show full text]
  • Natural Products That Target the Arginase in Leishmania Parasites Hold Therapeutic Promise
    microorganisms Review Natural Products That Target the Arginase in Leishmania Parasites Hold Therapeutic Promise Nicola S. Carter, Brendan D. Stamper , Fawzy Elbarbry , Vince Nguyen, Samuel Lopez, Yumena Kawasaki , Reyhaneh Poormohamadian and Sigrid C. Roberts * School of Pharmacy, Pacific University, Hillsboro, OR 97123, USA; cartern@pacificu.edu (N.S.C.); stamperb@pacificu.edu (B.D.S.); fawzy.elbarbry@pacificu.edu (F.E.); nguy6477@pacificu.edu (V.N.); lope3056@pacificu.edu (S.L.); kawa4755@pacificu.edu (Y.K.); poor1405@pacificu.edu (R.P.) * Correspondence: sroberts@pacificu.edu; Tel.: +1-503-352-7289 Abstract: Parasites of the genus Leishmania cause a variety of devastating and often fatal diseases in humans worldwide. Because a vaccine is not available and the currently small number of existing drugs are less than ideal due to lack of specificity and emerging drug resistance, the need for new therapeutic strategies is urgent. Natural products and their derivatives are being used and explored as therapeutics and interest in developing such products as antileishmanials is high. The enzyme arginase, the first enzyme of the polyamine biosynthetic pathway in Leishmania, has emerged as a potential therapeutic target. The flavonols quercetin and fisetin, green tea flavanols such as catechin (C), epicatechin (EC), epicatechin gallate (ECG), and epigallocatechin-3-gallate (EGCG), and cinnamic acid derivates such as caffeic acid inhibit the leishmanial enzyme and modulate the host’s immune response toward parasite defense while showing little toxicity to the host. Quercetin, EGCG, gallic acid, caffeic acid, and rosmarinic acid have proven to be effective against Leishmania Citation: Carter, N.S.; Stamper, B.D.; in rodent infectivity studies.
    [Show full text]
  • The Epidemiology and Clinical Features of Balamuthia Mandrillaris Disease in the United States, 1974 – 2016
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Clin Infect Manuscript Author Dis. Author manuscript; Manuscript Author available in PMC 2020 August 28. Published in final edited form as: Clin Infect Dis. 2019 May 17; 68(11): 1815–1822. doi:10.1093/cid/ciy813. The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974 – 2016 Jennifer R. Cope1, Janet Landa1,2, Hannah Nethercut1,3, Sarah A. Collier1, Carol Glaser4, Melanie Moser5, Raghuveer Puttagunta1, Jonathan S. Yoder1, Ibne K. Ali1, Sharon L. Roy6 1Waterborne Disease Prevention Branch, Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA 2James A. Ferguson Emerging Infectious Diseases Fellowship Program, Baltimore, MD, USA 3Oak Ridge Institute for Science and Education, Oak Ridge, TN, USA 4Kaiser Permanente, San Francisco, CA, USA 5Office of Financial Resources, Centers for Disease Control and Prevention Atlanta, GA, USA 6Parasitic Diseases Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA Abstract Background—Balamuthia mandrillaris is a free-living ameba that causes rare, nearly always fatal disease in humans and animals worldwide. B. mandrillaris has been isolated from soil, dust, and water. Initial entry of Balamuthia into the body is likely via the skin or lungs. To date, only individual case reports and small case series have been published. Methods—The Centers for Disease Control and Prevention (CDC) maintains a free-living ameba (FLA) registry and laboratory. To be entered into the registry, a Balamuthia case must be laboratory-confirmed.
    [Show full text]
  • Epigallocathechin-O-3-Gallate Inhibits Trypanothione Reductase of Leishmania Infantum, Causing Alterations in Redox Balance And
    ORIGINAL RESEARCH published: 25 March 2021 doi: 10.3389/fcimb.2021.640561 Epigallocathechin-O-3-Gallate Inhibits Trypanothione Reductase of Leishmania infantum, Causing Alterations in Redox Balance and Edited by: Leading to Parasite Death Brice Rotureau, Institut Pasteur, France Job D. F. Inacio 1, Myslene S. Fonseca 1, Gabriel Limaverde-Sousa 2, Ana M. Tomas 3,4, Reviewed by: Helena Castro 3 and Elmo E. Almeida-Amaral 1* Wanderley De Souza, Federal University of Rio de Janeiro, 1 Laborato´ rio de Bioqu´ımica de Tripanosomatideos, Instituto Oswaldo Cruz (IOC), Fundac¸ão Oswaldo Cruz – FIOCRUZ, Brazil Rio de Janeiro, Brazil, 2 Laborato´ rio de Esquistossomose Experimental, Instituto Osvaldo Cruz, Fundac¸ão Oswaldo Cruz – Andrea Ilari, FIOCRUZ, Rio de Janeiro, Brazil, 3 i3S—Instituto de Investigac¸ão e Inovac¸ão em Sau´ de, Universidade do Porto, Porto, Italian National Research Portugal, 4 ICBAS—Instituto de Cieˆ ncias Biome´ dicas Abel Salazar, Universidade do Porto, Porto, Portugal Council, Italy Marina Gramiccia, ISS, Italy Leishmania infantum is a protozoan parasite that causes a vector borne infectious disease *Correspondence: in humans known as visceral leishmaniasis (VL). This pathology, also caused by L. Elmo E. Almeida-Amaral donovani, presently impacts the health of 500,000 people worldwide, and is treated elmo@ioc.fiocruz.br with outdated anti-parasitic drugs that suffer from poor treatment regimens, severe side Specialty section: effects, high cost and/or emergence of resistant parasites. In previous works we have This article was submitted to disclosed the anti-Leishmania activity of (-)-Epigallocatechin 3-O-gallate (EGCG), a Parasite and Host, flavonoid compound present in green tea leaves.
    [Show full text]
  • Treatment of Visceral Leishmaniasis with Intravenous Pentamidine And
    International Journal of Infectious Diseases 14 (2010) e522–e525 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Case Report Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure — a case report and brief review of the literature Jan Rybniker a, Valentin Goede a, Jessica Mertens b, Monika Ortmann c, Wolfgang Kulas d, Matthias Kochanek a, Thomas Benzing e, Jose´ R. Arribas f, Gerd Fa¨tkenheuer a,* a 1st Department of Internal Medicine, University of Cologne, 50924 Cologne, Germany b Department of Gastroenterology, University of Cologne, Cologne, Germany c Institute of Pathology, University of Cologne, Cologne, Germany d Nephrologisches Zentrum Mettmann, Mettmann, Germany e Department of Medicine and Centre for Molecular Medicine, University of Cologne, Cologne, Germany f Enfermedades Infecciosas, Hospital Universitario La Paz, Madrid, Spain ARTICLE INFO SUMMARY Article history: We report the case of an HIV-positive patient with visceral leishmaniasis and several relapses after Received 3 March 2009 treatment with the two first-line anti-leishmanial drugs, liposomal amphotericin B and miltefosine. End- Accepted 4 June 2009 stage renal failure occurred in 2007 when the patient was on long-term treatment with miltefosine. A Corresponding Editor: William Cameron, relapse of leishmaniasis in 2008 was successfully treated with a novel combination regimen of Ottawa, Canada intravenous pentamidine and oral fluconazole. Secondary prophylaxis with fluconazole monotherapy did not prevent parasitological relapse of leishmaniasis. Keywords: ß 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Visceral leishmaniasis HIV Fluconazole Pentamidine Miltefosine Renal failure 1.
    [Show full text]
  • Lopinavir, an HIV-1 Peptidase Inhibitor, Induces Alteration on the Lipid Metabolism of Cambridge.Org/Par Leishmania Amazonensis Promastigotes
    Parasitology Lopinavir, an HIV-1 peptidase inhibitor, induces alteration on the lipid metabolism of cambridge.org/par Leishmania amazonensis promastigotes 1 2 3 Special Issue Research Karina M. Rebello , Valter V. Andrade-Neto , Aline A. Zuma , 3 4 Article Maria Cristina M. Motta , Claudia Regina B. Gomes , Marcus Vinícius N. de Souza4, Geórgia C. Atella5, Marta H. Branquinha6, ‡Both authors share senior authorship. André L. S. Santos6, Eduardo Caio Torres-Santos2,‡ and Claudia M. d’Avila-Levy1,‡ Cite this article: Rebello KM et al (2018). Lopinavir, an HIV-1 peptidase inhibitor, 1Laboratório de Estudos Integrados em Protozoologia, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz induces alteration on the lipid metabolism of (FIOCRUZ), Rio de Janeiro, Brazil; 2Laboratório de Bioquímica de Tripanosomatídeos, Instituto Oswaldo Cruz, Leishmania amazonensis promastigotes. 3 145 – FIOCRUZ, Rio de Janeiro, Brazil; Laboratório de Ultraestrutura Celular Hertha Meyer, Instituto de Biofísica Carlos Parasitology , 1304 1310. https://doi.org/ 4 10.1017/S0031182018000823 Chagas Filho, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil; Laboratório de Síntese de Fármacos, Farmanguinhos, FIOCRUZ, Rio de Janeiro, Brazil; 5Instituto de Bioquímica Médica, UFRJ, Rio de Received: 8 February 2018 Janeiro, Brazil and 6Laboratório de Investigação de Peptidases, Instituto de Microbiologia Paulo de Góes, UFRJ, Revised: 3 April 2018 Rio de Janeiro, Brazil Accepted: 5 April 2018 First published online: 28 May 2018 Key words: Abstract Aspartyl; chemotherapy; co-infection; The anti-leishmania effects of HIV peptidase inhibitors (PIs) have been widely reported; how- leishmaniasis; trypanosomatids ever, the biochemical target and mode of action are still a matter of controversy in Leishmania Author for correspondence: parasites.
    [Show full text]
  • Interactions with Protease Inhibitors Charts Revised February 2018
    www.hiv-druginteractions.org Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium Ertapenem Bupivacaine Erythromycin Cisatracurium Ethambutol Desflurane Ethionamide Dexmedetomidine Flucloxacillin Enflurane Gentamicin Ephedrine Imipenem/Cilastatin Halothane Isoniazid Isoflurane Kanamycin Ketamine Levofloxacin Linezolid Nitrous oxide Meropenem Propofol Metronidazole Rocuronium Moxifloxacin Sevoflurane Nitrofurantoin Sufentanil Ofloxacin Suxamethonium (succinylcholine) Para-aminosalicylic acid Tetracaine Penicillins Thiopental for distribution. for Pyrazinamide Tizanidine Rifabutin Vecuronium Rifampicin Analgesics Rifapentine Alfentanil Rifaximin Aspirin Spectinomycin Buprenorphine Streptomycin Celecoxib Sulfadiazine Codeine Telithromycin Tetracyclines
    [Show full text]
  • Clinical Trial Protocol
    Research Protocol - A randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidine Item Type Other Authors Hailu, Asrat; Diro, Ermias; Kolja, Stille; Ritmeijer, Koert; Yifru, Sisay; van Griensven, Johan; Zijlstra, Ed; Dorlo, Thomas Rights These materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https:// i.creativecommons.org/l/by/4.0/88x31.png Download date 24/09/2021 17:38:21 Link to Item http://hdl.handle.net/10144/332058 CLINICAL TRIAL PROTOCOL A randomized trial of AmBisome® monotherapy and combination of AmBisome® and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidine Name of product(s)/ Liposomal amphotericin B (AmBisome®) Project code Miltefosine (Impavido®) Drug Class Polyene, alkylphosphocholine Phase Phase III Indication HIV and VL co-infected patients Protocol Number HIV/VL 0511 Sponsor DNDi, Chemin Louis Dunant, 15, 1202 GENEVA, Switzerland Phone: +41 22 906 9230 Co-sponsor MSF Operational Centre Amsterdam Confidential Page 1 of 61 FINAL Version 2 dated 29th November 2012 Protocol number HIV/VL 0511 AmBisome®, Miltefosine 2nd Version Coordinating Principal Investigators Investigator/Principal Coordinating Investigator: Prof Asrat Hailu Investigator Gondar site investigator: Dr Ermias Diro Abdurafi site investigator: Dr. Stille Kolja , Médecins Sans Frontières (MSF) Co-investigators Dr Koert Ritmeijer, Médecins Sans Frontières, Amsterdam Dr Sisay Yifru, College of Health Sciences, Gondar University Dr Johan van Griensven, Institute of Tropical Medicine, Antwerp Prof Ed Zijlstra, DNDi Dr.
    [Show full text]
  • Review Campylobacter As a Major Foodborne Pathogen
    REVIEW CAMPYLOBACTER AS A MAJOR FOODBORNE PATHOGEN: A REVIEW OF ITS CHARACTERISTICS, PATHOGENESIS, ANTIMICROBIAL RESISTANCE AND CONTROL Ahmed M. Ammar1, El-Sayed Y. El-Naenaeey1, Marwa I. Abd El-Hamid1, Attia A. El-Gedawy2 and Rania M. S. El- Malt*3 Address: Rania Mohamed Saied El-Malt 1 Zagazig University, Faculty of Veterinary Medicine, Department of Microbiology, 19th Saleh Abo Rahil Street, El-Nahal, 44519, Zagazig, Sharkia, Egypt 2 Animal health Research Institute, Department of Bacteriology, Tuberculosis unit, Nadi El-Seid Street,12618 Dokki, Giza, Egypt 3 Animal health Research Institute, Department of Microbiology, El-Mohafza Street, 44516, Zagazig, Sharkia, Egypt, +201061463064 *Corresponding author: [email protected] ABSTRACT Campylobacter, mainly Campylobacter jejuni is viewed as one of the most well-known reasons of foodborne bacterial diarrheal sickness in people around the globe. The genus Campylobacter contains 39 species (spp.) and 16 sub spp. Campylobacter is microaerophilic, Gram negative, spiral- shaped rod with characteristic cork screw motility. It is colonizing the digestive system of numerous wild and household animals and birds, particularly chickens. Intestinal colonization brings about transporter/carrier healthy animals. Consequently, the utilization of contaminated meat, especially chicken meat is the primary source of campylobacteriosis in humans and chickens are responsible for an expected 80% of human campylobacter infection. Interestingly, in contrast with the most recent published reviews that cover specific aspects of campylobacter/campylobacteriosis, this review targets the taxonomy, biological characteristics, identification and habitat of Campylobacter spp. Moreover, it discusses the pathogenesis, resistance to antimicrobial agents and public health significance of Campylobacter spp. Finally, it focuses on the phytochemicals as intervention strategies used to reduce Campylobacter spp.in poultry production.
    [Show full text]